News
Excellamol has received a promising review from the BTR-NTA Committee! (Aug. 12, 2025)
Excellamol was honored to be selected for the BTR-NTA program (www.tessajowellbraincancermission.org/strategic-programmes/btr-nta), held on May 21, 2025, in Edinburgh, Scotland. The company showcased its Self-Depot™ OncoPDC platform and XM161-SN38, an FDA Orphan Drug Designated therapy for brain cancers, and engaged with eighteen leading experts across the therapeutic development pathway. Feedback on preclinical progress, manufacturing, regulatory strategy, biomarkers, and trial design will help guide Excellamol’s next steps in advancing therapies for patients with brain cancer.
